Arbutus Biopharma ( NASDAQ:ABUS - Get Free Report ) last issued its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). The business had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.54 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. Analysts predict that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.